Last edition
News about "Samsung Biologics"
By deploying the ExellenS framework across its manufacturing network—with standardised designs, unified processes, and advanced digital integration—Samsung Biologics ensures plant equivalency, operational speed, and seamless manufacturing continuity.
Samsung Biologics | 10/10/2025 | By Dineshwori | 163
Samsung Biologics has announced its financial results for the second quarter of fiscal year 2025, posting strong growth across both consolidated and standalone metrics.
Samsung Biologics | 23/07/2025 | By Dineshwori | 1102
Samsung Biologics Announces Manufacturing Deal with European Pharmaceutical Company
Samsung Biologics is set to add antibody-drug conjugate (ADC) services to its portfolio, with a dedicated facility to be completed by the end of this year.
Samsung Biologics | 20/11/2024 | By Aishwarya | 251
Samsung Biologics Secures ISO Certifications for its Business Excellence
The certifications were presented by the British Standards Institution (BSI) during a ceremony held at Samsung Biologics' headquarters.
Samsung Biologics | 11/11/2024 | By Aishwarya | 442
Samsung Biologics Inks Manufacturing Deal with Asian Pharmaceutical Company
With the latest agreement, the company's accumulated contract for 2024 surpasses USD 3.3 billion.
Samsung Biologics | 22/10/2024 | By Aishwarya | 359
Samsung Biologics Develops High-Concentration Formulation Platform for Drug Development
S-HiCon can proactively identify unintended pH changes, enhance formulation stability, and reduce viscosity to ensure efficacy and maximize drug delivery.
Samsung Biologics | 15/10/2024 | By Aishwarya | 363
Samsung Biologics Introduces Development Platforms for Enhanced Therapeutic Efficacy
Samsung Biologics has unveiled a series of proprietary development platforms as part of continued efforts to ensure high-quality development and provide client-tailored services.<br />
Samsung Biologics | 26/09/2024 | By Aishwarya | 405
Samsung Biologics Joins Pharmaceutical Supply Chain Initiative as Supplier Partner
Samsung Biologics, a global contract development and manufacturing organization (CDMO), has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner.
Samsung Biologics | 08/08/2024 | By Aishwarya | 527
Samsung Biologics set to begin construction of new $1.5B plant
The investment will add 180,000 litres of capacity to the complex in Incheon, bringing total capacity to 784,000 litres, the most at a single site in the industry
Samsung Biologics | 03/05/2023 | By Sudeep Soparkar | 661
Samsung Biologics eyes strategic expansion in Korea
The company plans to begin construction in the first half of 2023 and commence operations in 2025
<br />
Samsung Biologics | 21/03/2023 | By Sudeep Soparkar | 844
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy